These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15916578)

  • 21. Successful treatment of persistent melanoma in situ with 5% imiquimod cream.
    Muñoz CM; Sánchez JL; Martín-García RF
    Dermatol Surg; 2004 Dec; 30(12 Pt 2):1543-5. PubMed ID: 15606836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resolution of tinea pedis with imiquimod cream 5% in a patient with nodular basal cell carcinoma.
    Stashower ME
    Cutis; 2006 Jul; 78(1):66-9. PubMed ID: 16903324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imiquimod in the treatment of extensive recurrent lentigo maligna.
    Kamin A; Eigentler TK; Radny P; Bauer J; Weide B; Garbe C
    J Am Acad Dermatol; 2005 Feb; 52(2 Suppl 1):51-2. PubMed ID: 15692515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of imiquimod in treating infantile haemangiomas: cause for concern?
    Hussain W; Judge MR
    Clin Exp Dermatol; 2009 Oct; 34(7):e257. PubMed ID: 19508566
    [No Abstract]   [Full Text] [Related]  

  • 25. Does imiquimod work in infantile hemangiomas?
    Czernik A; Bystryn JC
    J Am Acad Dermatol; 2007 Sep; 57(3):535; author reply 536. PubMed ID: 17707162
    [No Abstract]   [Full Text] [Related]  

  • 26. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage.
    Neville JA; Williford PM; Jorizzo JL
    J Drugs Dermatol; 2007 Sep; 6(9):910-4. PubMed ID: 17941362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective hemangioma cell dysfunction and apoptosis triggered by in vitro treatment with imiquimod.
    Rocco R; Alegre N; Pozner R; Wainstok R; Gazzaniga S
    Toxicol Lett; 2018 May; 288():82-88. PubMed ID: 29410238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe.
    Schulze HJ; Cribier B; Requena L; Reifenberger J; Ferrándiz C; Garcia Diez A; Tebbs V; McRae S
    Br J Dermatol; 2005 May; 152(5):939-47. PubMed ID: 15888150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of lymphangioma circumscriptum with topical imiquimod 5% cream.
    Wang JY; Liu LF; Mao XH
    Dermatol Surg; 2012 Sep; 38(9):1566-9. PubMed ID: 22805499
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream.
    Deeths MJ; Chapman JT; Dellavalle RP; Zeng C; Aeling JL
    J Am Acad Dermatol; 2005 Feb; 52(2):275-80. PubMed ID: 15692473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topical timolol for small infantile hemangioma: a new therapy option.
    Weissenstein A; Straeter A; Villalon G; Bittmann S
    Turk J Pediatr; 2012; 54(2):156-8. PubMed ID: 22734302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A therapeutic approach to perianal extramammary Paget's disease: topical imiquimod can be useful to prevent or defer surgery.
    Vereecken P; Awada A; Ghanem G; Marques da Costa C; Larsimont D; Simoens C; Mendes da Costa P; Hendlisz A
    Med Sci Monit; 2007 Jun; 13(6):CS75-7. PubMed ID: 17534239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of an extensive superficial basal cell carcinoma of the face with imiquimod 5% cream.
    Micali M; Nasca MR; Musumeci ML
    Int J Tissue React; 2005; 27(3):111-4. PubMed ID: 16372477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 5% imiquimod cream for the treatment of large superficial basal cell carcinoma.
    Shumack S; Gebauer K; Quirk C; Macdonald K; Walters SA; Owens M
    Arch Dermatol; 2004 Oct; 140(10):1286-7. PubMed ID: 15492202
    [No Abstract]   [Full Text] [Related]  

  • 35. Imiquimod and superficial skin cancers.
    Naylor M
    J Drugs Dermatol; 2005; 4(5):598-606. PubMed ID: 16167419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up.
    Schiessl C; Wolber C; Tauber M; Offner F; Strohal R
    J Drugs Dermatol; 2007 May; 6(5):507-13. PubMed ID: 17679185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks.
    Quirk C; Gebauer K; Owens M; Stampone P
    Australas J Dermatol; 2006 Nov; 47(4):258-65. PubMed ID: 17034468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fractional carbon dioxide laser-assisted drug delivery of topical timolol solution for the treatment of deep infantile hemangioma: a pilot study.
    Ma G; Wu P; Lin X; Chen H; Hu X; Jin Y; Qiu Y
    Pediatr Dermatol; 2014; 31(3):286-91. PubMed ID: 24602019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience.
    Tillman DK; Carroll MT
    Cutis; 2007 Mar; 79(3):241-8. PubMed ID: 17674590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara).
    Didona B; Benucci R; Amerio P; Canzona F; Rienzo O; Cavalieri R
    Br J Dermatol; 2004 Jun; 150(6):1198-201. PubMed ID: 15214911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.